AC Immune SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by AC Immune SA, a foreign private issuer, for the month of September 2024. The report, dated September 19, 2024, discloses a significant executive appointment and departure within the company's leadership team.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change reported is the appointment of Dr. Anke Post, MD PhD, as Chief Medical Officer (CMO) and a member of the Executive Committee, effective September 19, 2024. Concurrently, Dr. Nuno Mendonça, MD, the current CMO, is leaving the company in September 2024 to pursue other professional opportunities.
Management Commentary and Risks
Management highlights Dr. Post's extensive background in neuroscience and drug development, including prior roles as CMO at GeNeuro SA, Senior Vice President at UniQure NV, and leadership positions at Roche, Eli Lilly, Novartis, FeetMe SAS, and Idorsia Pharmaceutical Ltd. The filing expresses gratitude to Dr. Mendonça for his contributions. No specific risks, contingencies, or unusual items are detailed in this report.
Key Facts for Investor Verification
- Dr. Anke Post has been appointed Chief Medical Officer and joined the Executive Committee.
- Dr. Nuno Mendonça is departing the company in September 2024.
- Dr. Post's recent experience includes serving as CMO at GeNeuro SA (Jan 2024–Sep 2024) and leading clinical development at UniQure NV.
- This filing contains no financial data or updated guidance for the period.